baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

SHIONOGI + CO. LTD/ JP3347200002 /

23/01/2025 09:07:17	Chg. -0.1000	Volume	Bid11:32:09	Ask11:32:09	Market Capitalization	Dividend Y.	P/E Ratio
13.2000EUR	-0.75%	0 Turnover: 0.0000	13.2000Bid Size: 150	14.5000Ask Size: 150	3.91 bill.EUR	-	-

GlobeNewswire 23/05/2024 Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Preval...

GlobeNewswire 09/05/2024 Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Ni...

GlobeNewswire 07/05/2024 Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal

GlobeNewswire 03/04/2024 Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire 06/03/2024 Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference

GlobeNewswire 22/02/2024 Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference

GlobeNewswire 19/02/2024 InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery

GlobeNewswire 07/02/2024 Alleo Labs Announces Publication on the Use of Artificial Intelligence in Neuroscience Drug Discover...

GlobeNewswire 22/01/2024 Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resourc...

GlobeNewswire 10/11/2023 Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...

GlobeNewswire 01/11/2023 Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for...

GlobeNewswire 21/10/2023 F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TI...

GlobeNewswire 20/09/2023 OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs

GlobeNewswire 22/12/2021 Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Ne...

GlobeNewswire 04/11/2021 Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

TeleTrader 01/11/2021 Shionogi to start COVID vaccine Phase 3 trial

GlobeNewswire 23/08/2021 Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

TeleTrader 25/07/2021 Japanese company tests anti-COVID drug - report

TeleTrader 27/06/2021 Japanese Shionogi to produce 60M doses in 2022

GlobeNewswire 13/05/2021 Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results

GlobeNewswire 27/04/2021 InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration

GlobeNewswire 05/04/2021 Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

GlobeNewswire 05/02/2021 CHNC Saga, Metamorphosis, and Transformation

GlobeNewswire 13/11/2020 AIM ImmunoTech Provides Third Quarter 2020 Business Update

GlobeNewswire 30/10/2020 BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year

SHIONOGI + CO. LTD/ JP3347200002 /

If you wish to receive reply to your feedback, please provide your email address.